2ht8 › Citations

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ
Nature 443 45-9 (2006)
Related entries: 2ht5, 2ht7, 2htq, 2htr, 2htu, 2htv, 2htw, 2hty, 2hu0, 2hu4

Cited: 427 times
EuropePMC logo PMID: 16915235

Abstract

The worldwide spread of H5N1 avian influenza has raised concerns that this virus might acquire the ability to pass readily among humans and cause a pandemic. Two anti-influenza drugs currently being used to treat infected patients are oseltamivir (Tamiflu) and zanamivir (Relenza), both of which target the neuraminidase enzyme of the virus. Reports of the emergence of drug resistance make the development of new anti-influenza molecules a priority. Neuraminidases from influenza type A viruses form two genetically distinct groups: group-1 contains the N1 neuraminidase of the H5N1 avian virus and group-2 contains the N2 and N9 enzymes used for the structure-based design of current drugs. Here we show by X-ray crystallography that these two groups are structurally distinct. Group-1 neuraminidases contain a cavity adjacent to their active sites that closes on ligand binding. Our analysis suggests that it may be possible to exploit the size and location of the group-1 cavity to develop new anti-influenza drugs.

Articles - 2ht8 mentioned but not cited (3)

  1. Computational studies of H5N1 influenza virus resistance to oseltamivir. Wang NX, Zheng JJ. Protein Sci. 18 707-715 (2009)
  2. The influence of 150-cavity binders on the dynamics of influenza A neuraminidases as revealed by molecular dynamics simulations and combined clustering. Greenway KT, LeGresley EB, Pinto BM. PLoS ONE 8 e59873 (2013)
  3. Molecular-level simulation of pandemic influenza glycoproteins. Amaro RE, Li WW. Methods Mol. Biol. 819 575-594 (2012)


Reviews citing this publication (74)

  1. Avian influenza virus (H5N1): a threat to human health. Peiris JS, de Jong MD, Guan Y. Clin. Microbiol. Rev. 20 243-267 (2007)
  2. Antiviral agents active against influenza A viruses. De Clercq E. Nat Rev Drug Discov 5 1015-1025 (2006)
  3. The war against influenza: discovery and development of sialidase inhibitors. von Itzstein M. Nat Rev Drug Discov 6 967-974 (2007)
  4. Influenza hemagglutinin and neuraminidase membrane glycoproteins. Gamblin SJ, Skehel JJ. J. Biol. Chem. 285 28403-28409 (2010)
  5. Structures of influenza A proteins and insights into antiviral drug targets. Das K, Aramini JM, Ma LC, Krug RM, Arnold E. Nat. Struct. Mol. Biol. 17 530-538 (2010)
  6. Evolutionary biochemistry: revealing the historical and physical causes of protein properties. Harms MJ, Thornton JW. Nat. Rev. Genet. 14 559-571 (2013)
  7. Current and future antiviral therapy of severe seasonal and avian influenza. Beigel J, Bray M. Antiviral Res. 78 91-102 (2008)
  8. Bat-derived influenza-like viruses H17N10 and H18N11. Wu Y, Wu Y, Tefsen B, Shi Y, Gao GF. Trends Microbiol. 22 183-191 (2014)
  9. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance. Ferraris O, Lina B. J. Clin. Virol. 41 13-19 (2008)
  10. Approved Antiviral Drugs over the Past 50 Years. De Clercq E, Li G. Clin. Microbiol. Rev. 29 695-747 (2016)
  11. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. McKimm-Breschkin JL. Influenza Other Respir Viruses 7 Suppl 1 25-36 (2013)
  12. The sweet spot: defining virus-sialic acid interactions. Stencel-Baerenwald JE, Reiss K, Reiter DM, Stehle T, Dermody TS. Nat. Rev. Microbiol. 12 739-749 (2014)
  13. Molecular strategies to inhibit the replication of RNA viruses. Leyssen P, De Clercq E, Neyts J. Antiviral Res. 78 9-25 (2008)
  14. The potential impact of neuraminidase inhibitor resistant influenza. Lackenby A, Thompson CI, Democratis J. Curr. Opin. Infect. Dis. 21 626-638 (2008)
  15. Influenza neuraminidase. Air GM. Influenza Other Respir Viruses 6 245-256 (2012)
  16. Influenza neuraminidase: a druggable target for natural products. Grienke U, Schmidtke M, von Grafenstein S, Kirchmair J, Liedl KR, Rollinger JM. Nat Prod Rep 29 11-36 (2012)
  17. Antiviral combinations for severe influenza. Dunning J, Baillie JK, Cao B, Hayden FG, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Lancet Infect Dis 14 1259-1270 (2014)
  18. Neuraminidase inhibitor resistance in influenza viruses. Reece PA. J. Med. Virol. 79 1577-1586 (2007)
  19. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection. Lee SM, Yen HL. Antiviral Res. 96 391-404 (2012)
  20. Antiviral strategies against influenza virus: towards new therapeutic approaches. Loregian A, Mercorelli B, Nannetti G, Compagnin C, Palù G. Cell. Mol. Life Sci. 71 3659-3683 (2014)
  21. Function and 3D structure of the N-glycans on glycoproteins. Nagae M, Yamaguchi Y. Int J Mol Sci 13 8398-8429 (2012)
  22. Anti-influenza agents from Traditional Chinese Medicine. Ge H, Wang YF, Xu J, Gu Q, Liu HB, Xiao PG, Zhou J, Liu Y, Yang Z, Su H. Nat Prod Rep 27 1758-1780 (2010)
  23. Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Kamali A, Holodniy M. Infect Drug Resist 6 187-198 (2013)
  24. Dissecting conformational contributions to glycosidase catalysis and inhibition. Speciale G, Thompson AJ, Davies GJ, Williams SJ. Curr. Opin. Struct. Biol. 28 1-13 (2014)
  25. Emerging antiviral targets for influenza A virus. Krug RM, Aramini JM. Trends Pharmacol. Sci. 30 269-277 (2009)
  26. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Burnham AJ, Baranovich T, Govorkova EA. Antiviral Res. 100 520-534 (2013)
  27. New antivirals and drug resistance. Colman PM. Annu. Rev. Biochem. 78 95-118 (2009)
  28. Avian influenza A (H5N1) infection: targets and strategies for chemotherapeutic intervention. De Clercq E, Neyts J. Trends Pharmacol Sci 28 280-285 (2007)
  29. Drug resistance in influenza A virus: the epidemiology and management. Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Infect Drug Resist 10 121-134 (2017)
  30. Recent progress in structure-based anti-influenza drug design. Du J, Cross TA, Zhou HX. Drug Discov. Today 17 1111-1120 (2012)
  31. Connecting the study of wild influenza with the potential for pandemic disease. Runstadler J, Hill N, Hussein IT, Puryear W, Keogh M. Infect. Genet. Evol. 17 162-187 (2013)
  32. Recent advances in neuraminidase inhibitor development as anti-influenza drugs. Feng E, Ye D, Li J, Zhang D, Wang J, Zhao F, Hilgenfeld R, Zheng M, Jiang H, Liu H. ChemMedChem 7 1527-1536 (2012)
  33. The prospects and challenges of universal vaccines for influenza. Subbarao K, Matsuoka Y. Trends Microbiol. 21 350-358 (2013)
  34. An overview of influenza haemagglutinin and neuraminidase. Skehel J. Biologicals 37 177-178 (2009)
  35. Influenza genome analysis using pyrosequencing method: current applications for a moving target. Deyde VM, Gubareva LV. Expert Rev. Mol. Diagn. 9 493-509 (2009)
  36. Glycan-based high-affinity ligands for toxins and pathogen receptors. Kulkarni AA, Weiss AA, Iyer SS. Med Res Rev 30 327-393 (2010)
  37. Disease-associated carbohydrate-recognising proteins and structure-based inhibitor design. von Itzstein M. Curr. Opin. Struct. Biol. 18 558-566 (2008)
  38. Functional balance between neuraminidase and haemagglutinin in influenza viruses. Gaymard A, Le Briand N, Frobert E, Lina B, Escuret V. Clin. Microbiol. Infect. 22 975-983 (2016)
  39. Antivirals Targeting the Neuraminidase. Gubareva L, Mohan T. Cold Spring Harb Perspect Med 12 a038455 (2022)
  40. Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs. Tompa DR, Immanuel A, Srikanth S, Kadhirvel S. Int J Biol Macromol 172 524-541 (2021)
  41. New small-molecule drug design strategies for fighting resistant influenza A. Shen Z, Lou K, Wang W. Acta Pharm Sin B 5 419-430 (2015)
  42. Recent progress and challenges in the discovery of new neuraminidase inhibitors. Chamni S, De-Eknamkul W. Expert Opin Ther Pat 23 409-423 (2013)
  43. The potential for multidrug-resistant influenza. van der Vries E, Schutten M, Boucher CA. Curr. Opin. Infect. Dis. 24 599-604 (2011)
  44. From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs? Cheng CK, Tsai CH, Shie JJ, Fang JM. Future Med Chem 6 757-774 (2014)
  45. A new role of neuraminidase (NA) in the influenza virus life cycle: implication for developing NA inhibitors with novel mechanism of action. Yang J, Liu S, Du L, Jiang S. Rev. Med. Virol. 26 242-250 (2016)
  46. Learning from structure-based drug design and new antivirals targeting the ribonucleoprotein complex for the treatment of influenza. Monod A, Swale C, Tarus B, Tissot A, Delmas B, Ruigrok RW, Crépin T, Slama-Schwok A. Expert Opin Drug Discov 10 345-371 (2015)
  47. Unusual influenza A viruses in bats. Mehle A. Viruses 6 3438-3449 (2014)
  48. Winning the arms race by improving drug discovery against mutating targets. Anderson AC. ACS Chem. Biol. 7 278-288 (2012)
  49. Progress of small molecular inhibitors in the development of anti-influenza virus agents. Wu X, Wu X, Sun Q, Zhang C, Yang S, Li L, Jia Z. Theranostics 7 826-845 (2017)
  50. Graphical representation and mathematical characterization of protein sequences and applications to viral proteins. Ghosh A, Nandy A. Adv Protein Chem Struct Biol 83 1-42 (2011)
  51. Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond. Matthew AN, Leidner F, Lockbaum GJ, Henes M, Zephyr J, Hou S, Rao DN, Timm J, Rusere LN, Ragland DA, Paulsen JL, Prachanronarong K, Soumana DI, Nalivaika EA, Kurt Yilmaz N, Ali A, Schiffer CA. Chem Rev 121 3238-3270 (2021)
  52. Influenza Viruses: Harnessing the Crucial Role of the M2 Ion-Channel and Neuraminidase toward Inhibitor Design. Mtambo SE, Amoako DG, Somboro AM, Agoni C, Lawal MM, Gumede NS, Khan RB, Kumalo HM. Molecules 26 880 (2021)
  53. The Chemistry and Biological Activities of Mimosine: A Review. Nguyen BC, Tawata S. Phytother Res 30 1230-1242 (2016)
  54. The Interplay between the Host Receptor and Influenza Virus Hemagglutinin and Neuraminidase. Byrd-Leotis L, Cummings RD, Steinhauer DA. Int J Mol Sci 18 (2017)
  55. Antimicrobial strategies: an option to treat allergy? Papadopoulos NG, Papadopoulos NG, Konstantinou GN. Biomed. Pharmacother. 61 21-28 (2007)
  56. Avian influenza virus, a very sticky situation. von Itzstein M. Curr Opin Chem Biol 12 102-108 (2008)
  57. Recent advances in pharmacophore modeling and its application to anti-influenza drug discovery. Shin WJ, Seong BL. Expert Opin Drug Discov 8 411-426 (2013)
  58. Antiviral Approaches against Influenza Virus. Kumari R, Sharma SD, Kumar A, Ende Z, Mishina M, Wang Y, Falls Z, Samudrala R, Pohl J, Knight PR, Sambhara S. Clin Microbiol Rev 36 e0004022 (2023)
  59. Antiviral Potential of Natural Resources against Influenza Virus Infections. Eichberg J, Maiworm E, Oberpaul M, Czudai-Matwich V, Lüddecke T, Vilcinskas A, Hardes K. Viruses 14 2452 (2022)
  60. Viral enzymes. Mesters JR, Tan J, Hilgenfeld R. Curr. Opin. Struct. Biol. 16 776-786 (2006)
  61. Risk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivir. Gillman A. Infect Ecol Epidemiol 6 32870 (2016)
  62. Antiviral adhesion molecular mechanisms for influenza: W. G. Laver's lifetime obsession. Garman EF. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 370 20140034 (2015)
  63. Influenza Virus Neuraminidase Structure and Functions. McAuley JL, Gilbertson BP, Trifkovic S, Brown LE, McKimm-Breschkin JL. Front Microbiol 10 39 (2019)
  64. Intragenic compensation through the lens of deep mutational scanning. Azbukina N, Zharikova A, Ramensky V. Biophys Rev 14 1161-1182 (2022)
  65. Thirty-Five-Year History of Desialylated Lipoproteins Discovered by Vladimir Tertov. Glanz V, Bezsonov EE, Soldatov V, Orekhov AN. Biomedicines 10 1174 (2022)
  66. Zwitterionic structures: from physicochemical properties toward computer-aided drug designs. Yang Z, Li Q, Yang G. Future Med Chem 8 2245-2262 (2016)
  67. Co-infection of the respiratory epithelium, scene of complex functional interactions between viral, bacterial, and human neuraminidases. Escuret V, Terrier O. Front Microbiol 14 1137336 (2023)
  68. Conformation and Linkage Studies of Specific Oligosaccharides Related to H1N1, H5N1, and Human Flu for Developing the Second Tamiflu. Yoo E. Biomol Ther (Seoul) 22 93-99 (2014)
  69. Development of effective anti-influenza drugs: congeners and conjugates - a review. Shie JJ, Fang JM. J. Biomed. Sci. 26 84 (2019)
  70. Immune response in influenza virus infection and modulation of immune injury by viral neuraminidase. Jiang H, Zhang Z. Virol J 20 193 (2023)
  71. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target. Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Front Immunol 12 786617 (2021)
  72. Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy. Batool S, Chokkakula S, Song MS. Microorganisms 11 183 (2023)
  73. Inhibitors of influenza viruses replication: a patent evaluation (WO2013019828). Xie Y, Song W, Xiao W, Gu C, Xu W. Expert Opin Ther Pat 23 1517-1524 (2013)
  74. Recent Advances in Application of Computer-Aided Drug Design in Anti-Influenza A Virus Drug Discovery. Yu D, Wang L, Wang Y. Int J Mol Sci 23 4738 (2022)

Articles citing this publication (350)

  1. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Bloom JD, Gong LI, Baltimore D. Science 328 1272-1275 (2010)
  2. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ. Nature 453 1258-1261 (2008)
  3. The structural basis for an essential subunit interaction in influenza virus RNA polymerase. Obayashi E, Yoshida H, Kawai F, Shibayama N, Kawaguchi A, Nagata K, Tame JR, Park SY. Nature 454 1127-1131 (2008)
  4. Structural characterization of the 1918 influenza virus H1N1 neuraminidase. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA. J. Virol. 82 10493-10501 (2008)
  5. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. J. Virol. 83 10366-10373 (2009)
  6. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L, Barr IG. Antiviral Res. 73 228-231 (2007)
  7. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. Yen HL, Ilyushina NA, Salomon R, Hoffmann E, Webster RG, Govorkova EA. J. Virol. 81 12418-12426 (2007)
  8. Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase. Cheng LS, Amaro RE, Xu D, Li WW, Arzberger PW, McCammon JA. J. Med. Chem. 51 3878-3894 (2008)
  9. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. Khurana S, Suguitan AL, Rivera Y, Simmons CP, Lanzavecchia A, Sallusto F, Manischewitz J, King LR, Subbarao K, Golding H. PLoS Med. 6 e1000049 (2009)
  10. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H. Sci Transl Med 2 15ra5 (2010)
  11. Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment? Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, Lackenby A, Daniels R, Hay A. J. Virol. 84 6769-6781 (2010)
  12. The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, Wei J, Feng E, Shen J, Chen J, Liu D, He J, Yan J, Liu H, Jiang H, Teng M, Li X, Gao GF. Nat. Struct. Mol. Biol. 17 1266-1268 (2010)
  13. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, Ellis J, Bermingham A, Nicholson K, Zambon M. Clin. Infect. Dis. 48 389-396 (2009)
  14. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. PLoS Pathog. 4 e1000103 (2008)
  15. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, Govorkova EA. Antimicrob. Agents Chemother. 52 3889-3897 (2008)
  16. Reduced sensitivity of influenza A (H5N1) to oseltamivir. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. Emerging Infect. Dis. 13 1354-1357 (2007)
  17. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, Gubareva LV. Antimicrob. Agents Chemother. 54 1102-1110 (2010)
  18. A genetically engineered waterfowl influenza virus with a deletion in the stalk of the neuraminidase has increased virulence for chickens. Munier S, Larcher T, Cormier-Aline F, Soubieux D, Su B, Guigand L, Labrosse B, Cherel Y, Quéré P, Marc D, Naffakh N. J. Virol. 84 940-952 (2010)
  19. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Liu AL, Wang HD, Lee SM, Wang YT, Du GH. Bioorg. Med. Chem. 16 7141-7147 (2008)
  20. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Hurt AC, Holien JK, Barr IG. Antimicrob. Agents Chemother. 53 4433-4440 (2009)
  21. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. Duval X, van der Werf S, Blanchon T, Mosnier A, Bouscambert-Duchamp M, Tibi A, Enouf V, Charlois-Ou C, Vincent C, Andreoletti L, Tubach F, Lina B, Mentré F, Leport C, Bivir Study Group. PLoS Med. 7 e1000362 (2010)
  22. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Deyde VM, Okomo-Adhiambo M, Sheu TG, Wallis TR, Fry A, Dharan N, Klimov AI, Gubareva LV. Antiviral Res. 81 16-24 (2009)
  23. Glycosylation site alteration in the evolution of influenza A (H1N1) viruses. Sun S, Wang Q, Zhao F, Chen W, Li Z. PLoS ONE 6 e22844 (2011)
  24. Ligand-based dual target drug design for H1N1: swine flu--a preliminary first study. Chen CY, Chang YH, Bau DT, Huang HJ, Tsai FJ, Tsai CH, Chen CY. J. Biomol. Struct. Dyn. 27 171-178 (2009)
  25. Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble. Landon MR, Amaro RE, Baron R, Ngan CH, Ozonoff D, McCammon JA, Vajda S. Chem Biol Drug Des 71 106-116 (2008)
  26. Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations. Amaro RE, Cheng X, Ivanov I, Xu D, McCammon JA. J. Am. Chem. Soc. 131 4702-4709 (2009)
  27. Docking validation resources: protein family and ligand flexibility experiments. Mukherjee S, Balius TE, Rizzo RC. J Chem Inf Model 50 1986-2000 (2010)
  28. Mechanism of 150-cavity formation in influenza neuraminidase. Amaro RE, Swift RV, Votapka L, Li WW, Walker RC, Bush RM. Nat Commun 2 388 (2011)
  29. Structural basis for oseltamivir resistance of influenza viruses. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Martin SR, Daniels RS, Gregory V, Skehel JJ, Gamblin SJ, Hay AJ. Vaccine 27 6317-6323 (2009)
  30. Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). Su B, Wurtzer S, Rameix-Welti MA, Dwyer D, van der Werf S, Naffakh N, Clavel F, Labrosse B. PLoS ONE 4 e8495 (2009)
  31. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV. Antiviral Res. 85 381-388 (2010)
  32. Characterization of two distinct neuraminidases from avian-origin human-infecting H7N9 influenza viruses. Wu Y, Bi Y, Vavricka CJ, Sun X, Zhang Y, Gao F, Zhao M, Xiao H, Qin C, He J, Liu W, Yan J, Qi J, Gao GF. Cell Res. 23 1347-1355 (2013)
  33. Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site. Zhu X, Yang H, Guo Z, Yu W, Carney PJ, Li Y, Chen LM, Paulson JC, Donis RO, Tong S, Stevens J, Wilson IA. Proc. Natl. Acad. Sci. U.S.A. 109 18903-18908 (2012)
  34. Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC. J. Virol. 87 9290-9300 (2013)
  35. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition. Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF. PLoS Pathog. 7 e1002249 (2011)
  36. Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic Acid receptors. Zhu X, McBride R, Nycholat CM, Yu W, Paulson JC, Wilson IA. J. Virol. 86 13371-13383 (2012)
  37. Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus. Li Q, Sun X, Li Z, Liu Y, Vavricka CJ, Qi J, Gao GF. Proc. Natl. Acad. Sci. U.S.A. 109 18897-18902 (2012)
  38. Aurintricarboxylic acid inhibits influenza virus neuraminidase. Hung HC, Tseng CP, Yang JM, Ju YW, Tseng SN, Chen YF, Chao YS, Hsieh HP, Shih SR, Hsu JT. Antiviral Res. 81 123-131 (2009)
  39. Emergence and genetic variation of neuraminidase stalk deletions in avian influenza viruses. Li J, Zu Dohna H, Cardona CJ, Miller J, Carpenter TE. PLoS ONE 6 e14722 (2011)
  40. Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses. Uhlendorff J, Matrosovich T, Klenk HD, Matrosovich M. Arch. Virol. 154 945-957 (2009)
  41. Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus. Wang SQ, Du QS, Huang RB, Zhang DW, Chou KC. Biochem. Biophys. Res. Commun. 386 432-436 (2009)
  42. Metabolic engineering for the production of shikimic acid in an evolved Escherichia coli strain lacking the phosphoenolpyruvate: carbohydrate phosphotransferase system. Escalante A, Calderón R, Valdivia A, de Anda R, Hernández G, Ramírez OT, Gosset G, Bolívar F. Microb. Cell Fact. 9 21 (2010)
  43. Optimized hydrophobic interactions and hydrogen bonding at the target-ligand interface leads the pathways of drug-designing. Patil R, Das S, Stanley A, Yadav L, Sudhakar A, Varma AK. PLoS ONE 5 e12029 (2010)
  44. Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase. Rudrawar S, Dyason JC, Rameix-Welti MA, Rose FJ, Kerry PS, Russell RJ, van der Werf S, Thomson RJ, Naffakh N, von Itzstein M. Nat Commun 1 113 (2010)
  45. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA. PLoS Pathog. 6 e1000933 (2010)
  46. Role of permissive neuraminidase mutations in influenza A/Brisbane/59/2007-like (H1N1) viruses. Abed Y, Pizzorno A, Bouhy X, Boivin G. PLoS Pathog. 7 e1002431 (2011)
  47. Characterization of the influenza A H5N1 viruses of the 2008-09 outbreaks in India reveals a third introduction and possible endemicity. Chakrabarti AK, Pawar SD, Cherian SS, Koratkar SS, Jadhav SM, Pal B, Raut S, Thite V, Kode SS, Keng SS, Payyapilly BJ, Mullick J, Mishra AC. PLoS ONE 4 e7846 (2009)
  48. Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites. Maurer-Stroh S, Ma J, Lee RT, Sirota FL, Eisenhaber F. Biol. Direct 4 18; discussion 18 (2009)
  49. H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. van der Vries E, Collins PJ, Vachieri SG, Xiong X, Liu J, Walker PA, Haire LF, Hay AJ, Schutten M, Osterhaus AD, Martin SR, Boucher CA, Skehel JJ, Gamblin SJ. PLoS Pathog. 8 e1002914 (2012)
  50. Influenza virus neuraminidase: structure and function. Shtyrya YA, Mochalova LV, Bovin NV. Acta Naturae 1 26-32 (2009)
  51. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Abed Y, Nehmé B, Baz M, Boivin G. Antiviral Res. 77 163-166 (2008)
  52. Independent-Trajectories Thermodynamic-Integration Free-Energy Changes for Biomolecular Systems: Determinants of H5N1 Avian Influenza Virus Neuraminidase Inhibition by Peramivir. Lawrenz M, Baron R, McCammon JA. J Chem Theory Comput 5 1106-1116 (2009)
  53. A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. Bloom JD, Nayak JS, Baltimore D. PLoS ONE 6 e22201 (2011)
  54. AutoGrow: a novel algorithm for protein inhibitor design. Durrant JD, Amaro RE, McCammon JA. Chem Biol Drug Des 73 168-178 (2009)
  55. Detection of molecular markers of antiviral resistance in influenza A (H5N1) viruses using a pyrosequencing method. Deyde VM, Nguyen T, Bright RA, Balish A, Shu B, Lindstrom S, Klimov AI, Gubareva LV. Antimicrob. Agents Chemother. 53 1039-1047 (2009)
  56. Influenza A virus N5 neuraminidase has an extended 150-cavity. Wang M, Qi J, Liu Y, Vavricka CJ, Wu Y, Li Q, Gao GF. J. Virol. 85 8431-8435 (2011)
  57. Oseltamivir resistance during treatment of H7N9 infection. Hay AJ, Hayden FG. Lancet 381 2230-2232 (2013)
  58. Oseltamivir resistance mutation N294S in human influenza A(H5N1) virus in Egypt. Earhart KC, Elsayed NM, Saad MD, Gubareva LV, Nayel A, Deyde VM, Abdelsattar A, Abdelghani AS, Boynton BR, Mansour MM, Essmat HM, Klimov A, Shuck-Lee D, Monteville MR, Tjaden JA. J Infect Public Health 2 74-80 (2009)
  59. Structure of a heterotetrameric geranyl pyrophosphate synthase from mint (Mentha piperita) reveals intersubunit regulation. Chang TH, Hsieh FL, Ko TP, Teng KH, Liang PH, Wang AH. Plant Cell 22 454-467 (2010)
  60. Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules. Rameix-Welti MA, Zarantonelli ML, Giorgini D, Ruckly C, Marasescu M, van der Werf S, Alonso JM, Naffakh N, Taha MK. Infect. Immun. 77 3588-3595 (2009)
  61. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Rungrotmongkol T, Intharathep P, Malaisree M, Nunthaboot N, Kaiyawet N, Sompornpisut P, Payungporn S, Poovorawan Y, Hannongbua S. Biochem. Biophys. Res. Commun. 385 390-394 (2009)
  62. Two birds with one stone? Possible dual-targeting H1N1 inhibitors from traditional Chinese medicine. Chang SS, Huang HJ, Chen CY. PLoS Comput. Biol. 7 e1002315 (2011)
  63. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Du QS, Wang SQ, Chou KC. Biochem. Biophys. Res. Commun. 362 525-531 (2007)
  64. Evolution of drug resistance in multiple distinct lineages of H5N1 avian influenza. Hill AW, Guralnick RP, Wilson MJ, Habib F, Janies D. Infect. Genet. Evol. 9 169-178 (2009)
  65. Susceptibility of highly pathogenic H5N1 influenza viruses to the neuraminidase inhibitor oseltamivir differs in vitro and in a mouse model. Govorkova EA, Ilyushina NA, McClaren JL, Naipospos TS, Douangngeun B, Webster RG. Antimicrob. Agents Chemother. 53 3088-3096 (2009)
  66. Decreased neuraminidase activity is important for the adaptation of H5N1 influenza virus to human airway epithelium. Ilyushina NA, Bovin NV, Webster RG. J. Virol. 86 4724-4733 (2012)
  67. Avian influenza A/H5N1 neuraminidase expressed in yeast with a functional head domain. Yongkiettrakul S, Boonyapakron K, Jongkaewwattana A, Wanitchang A, Leartsakulpanich U, Chitnumsub P, Eurwilaichitr L, Yuthavong Y. J. Virol. Methods 156 44-51 (2009)
  68. Induced opening of influenza virus neuraminidase N2 150-loop suggests an important role in inhibitor binding. Wu Y, Qin G, Gao F, Liu Y, Vavricka CJ, Qi J, Jiang H, Yu K, Gao GF. Sci Rep 3 1551 (2013)
  69. A generic system for the expression and purification of soluble and stable influenza neuraminidase. Schmidt PM, Attwood RM, Mohr PG, Barrett SA, McKimm-Breschkin JL. PLoS ONE 6 e16284 (2011)
  70. Development of a surveillance scheme for equine influenza in the UK and characterisation of viruses isolated in Europe, Dubai and the USA from 2010-2012. Woodward AL, Rash AS, Blinman D, Bowman S, Chambers TM, Daly JM, Damiani A, Joseph S, Lewis N, McCauley JW, Medcalf L, Mumford J, Newton JR, Tiwari A, Bryant NA, Elton DM. Vet. Microbiol. 169 113-127 (2014)
  71. Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis. Sun J, Cai S, Yan N, Mei H. Eur J Med Chem 45 1008-1014 (2010)
  72. Prediction of biological functions on glycosylation site migrations in human influenza H1N1 viruses. Sun S, Wang Q, Zhao F, Chen W, Li Z. PLoS ONE 7 e32119 (2012)
  73. Active 1918 pandemic flu viral neuraminidase has distinct N-glycan profile and is resistant to trypsin digestion. Wu ZL, Ethen C, Hickey GE, Jiang W. Biochem. Biophys. Res. Commun. 379 749-753 (2009)
  74. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Richard M, Ferraris O, Erny A, Barthélémy M, Traversier A, Sabatier M, Hay A, Lin YP, Russell RJ, Lina B. Antimicrob. Agents Chemother. 55 2942-2952 (2011)
  75. Deletion of the aroK gene is essential for high shikimic acid accumulation through the shikimate pathway in E. coli. Chen K, Dou J, Tang S, Yang Y, Wang H, Fang H, Zhou C. Bioresour. Technol. 119 141-147 (2012)
  76. Molecular dynamics simulations suggest that electrostatic funnel directs binding of Tamiflu to influenza N1 neuraminidases. Le L, Lee EH, Hardy DJ, Truong TN, Schulten K. PLoS Comput. Biol. 6 (2010)
  77. Characterization of the complete genome of influenza A (H5N1) virus isolated during the 2006 outbreak in poultry in India. Ray K, Potdar VA, Cherian SS, Pawar SD, Jadhav SM, Waregaonkar SR, Joshi AA, Mishra AC. Virus Genes 36 345-353 (2008)
  78. Improving the Efficiency of Free Energy Calculations in the Amber Molecular Dynamics Package. Kaus JW, Pierce LT, Walker RC, McCammont JA. J Chem Theory Comput 9 (2013)
  79. A broad spectrum, one-step reverse-transcription PCR amplification of the neuraminidase gene from multiple subtypes of influenza A virus. Alvarez AC, Brunck ME, Boyd V, Lai R, Virtue E, Chen W, Bletchly C, Heine HG, Barnard R. Virol. J. 5 77 (2008)
  80. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir. Samson M, Abed Y, Desrochers FM, Hamilton S, Luttick A, Tucker SP, Pryor MJ, Boivin G. Antimicrob. Agents Chemother. 58 5220-5228 (2014)
  81. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses. Liu WC, Lin CY, Tsou YT, Jan JT, Wu SC. J. Virol. 89 7224-7234 (2015)
  82. Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors. Li P, Du R, Wang Y, Hou X, Wang L, Zhao X, Zhan P, Liu X, Rong L, Cui Q. Front Microbiol 11 182 (2020)
  83. Role of secondary sialic acid binding sites in influenza N1 neuraminidase. Sung JC, Van Wynsberghe AW, Amaro RE, Li WW, McCammon JA. J. Am. Chem. Soc. 132 2883-2885 (2010)
  84. Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation. Malaisree M, Rungrotmongkol T, Nunthaboot N, Aruksakunwong O, Intharathep P, Decha P, Sompornpisut P, Hannongbua S. Amino Acids 37 725-732 (2009)
  85. The evolutionary pattern of glycosylation sites in influenza virus (H5N1) hemagglutinin and neuraminidase. Chen W, Zhong Y, Qin Y, Sun S, Li Z. PLoS ONE 7 e49224 (2012)
  86. Understanding of known drug-target interactions in the catalytic pocket of neuraminidase subtype N1. Malaisree M, Rungrotmongkol T, Decha P, Intharathep P, Aruksakunwong O, Hannongbua S. Proteins 71 1908-1918 (2008)
  87. High-throughput neuraminidase substrate specificity study of human and avian influenza A viruses. Li Y, Cao H, Dao N, Luo Z, Yu H, Chen Y, Xing Z, Baumgarth N, Cardona C, Chen X. Virology 415 12-19 (2011)
  88. Molecular Characterizations of Surface Proteins Hemagglutinin and Neuraminidase from Recent H5Nx Avian Influenza Viruses. Yang H, Carney PJ, Mishin VP, Guo Z, Chang JC, Wentworth DE, Gubareva LV, Stevens J. J. Virol. 90 5770-5784 (2016)
  89. Streptococcus pneumoniae NanC: STRUCTURAL INSIGHTS INTO THE SPECIFICITY AND MECHANISM OF A SIALIDASE THAT PRODUCES A SIALIDASE INHIBITOR. Owen CD, Lukacik P, Potter JA, Sleator O, Taylor GL, Walsh MA. J. Biol. Chem. 290 27736-27748 (2015)
  90. Unique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses. Song MS, Marathe BM, Kumar G, Wong SS, Rubrum A, Zanin M, Choi YK, Webster RG, Govorkova EA, Webby RJ. J. Virol. 89 10891-10900 (2015)
  91. Computational assay of H7N9 influenza neuraminidase reveals R292K mutation reduces drug binding affinity. Woods CJ, Malaisree M, Long B, McIntosh-Smith S, Mulholland AJ. Sci Rep 3 3561 (2013)
  92. Design of oseltamivir analogs inhibiting neuraminidase of avian influenza virus H5N1. Rungrotmongkol T, Frecer V, De-Eknamkul W, Hannongbua S, Miertus S. Antiviral Res. 82 51-58 (2009)
  93. Detection of influenza A H1N1 and H3N2 mutations conferring resistance to oseltamivir using rolling circle amplification. Steain MC, Dwyer DE, Hurt AC, Kol C, Saksena NK, Cunningham AL, Wang B. Antiviral Res. 84 242-248 (2009)
  94. Inhibitor selectivity of a new class of oseltamivir analogs against viral neuraminidase over human neuraminidase enzymes. Albohy A, Mohan S, Zheng RB, Pinto BM, Cairo CW. Bioorg. Med. Chem. 19 2817-2822 (2011)
  95. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Mitrasinovic PM. Biophys. Chem. 140 35-38 (2009)
  96. Oseltamivir-zanamivir bitherapy compared to oseltamivir monotherapy in the treatment of pandemic 2009 influenza A(H1N1) virus infections. Escuret V, Cornu C, Boutitie F, Enouf V, Mosnier A, Bouscambert-Duchamp M, Gaillard S, Duval X, Blanchon T, Leport C, Gueyffier F, Van Der Werf S, Lina B. Antiviral Res. 96 130-137 (2012)
  97. Assembly of subtype 1 influenza neuraminidase is driven by both the transmembrane and head domains. da Silva DV, Nordholm J, Madjo U, Pfeiffer A, Daniels R. J. Biol. Chem. 288 644-653 (2013)
  98. Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy. Lawrenz M, Wereszczynski J, Amaro R, Walker R, Roitberg A, McCammon JA. Proteins 78 2523-2532 (2010)
  99. Pocket-space maps to identify novel binding-site conformations in proteins. Craig IR, Pfleger C, Gohlke H, Essex JW, Spiegel K. J Chem Inf Model 51 2666-2679 (2011)
  100. Structural basis for a class of nanomolar influenza A neuraminidase inhibitors. Kerry PS, Mohan S, Russell RJ, Bance N, Niikura M, Pinto BM. Sci Rep 3 2871 (2013)
  101. A water-swap reaction coordinate for the calculation of absolute protein-ligand binding free energies. Woods CJ, Malaisree M, Hannongbua S, Mulholland AJ. J Chem Phys 134 054114 (2011)
  102. Correlation analyses on binding affinity of sialic acid analogues and anti-influenza drugs with human neuraminidase using ab initio MO calculations on their complex structures--LERE-QSAR analysis (IV). Hitaoka S, Matoba H, Harada M, Yoshida T, Tsuji D, Hirokawa T, Itoh K, Chuman H. J Chem Inf Model 51 2706-2716 (2011)
  103. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006. Bauer K, Richter M, Wutzler P, Schmidtke M. Antiviral Res. 82 34-41 (2009)
  104. Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach. Karthick V, Shanthi V, Rajasekaran R, Ramanathan K. Appl. Biochem. Biotechnol. 167 237-249 (2012)
  105. Comment Structural biology: antiviral drugs fit for a purpose. Luo M. Nature 443 37-38 (2006)
  106. Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Bauer K, Dürrwald R, Schlegel M, Pfarr K, Topf D, Wiesener N, Dahse HM, Wutzler P, Schmidtke M. Med. Microbiol. Immunol. 201 61-72 (2012)
  107. Oseltamivir-resistant pandemic (H1N1) 2009 virus, South Korea. Yi H, Lee JY, Hong EH, Kim MS, Kwon D, Choi JH, Choi WY, Kim KS, Lee JK, Oh HB, Kang C. Emerging Infect. Dis. 16 1938-1942 (2010)
  108. The 2008-2009 H1N1 influenza virus exhibits reduced susceptibility to antibody inhibition: Implications for the prevalence of oseltamivir resistant variant viruses. Wu WL, Lau SY, Chen Y, Wang G, Mok BW, Wen X, Wang P, Song W, Lin T, Chan KH, Yuen KY, Chen H. Antiviral Res. 93 144-153 (2012)
  109. How does each substituent functional group of oseltamivir lose its activity against virulent H5N1 influenza mutants? Rungrotmongkol T, Udommaneethanakit T, Malaisree M, Nunthaboot N, Intharathep P, Sompornpisut P, Hannongbua S. Biophys. Chem. 145 29-36 (2009)
  110. Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir. Gillman A, Muradrasoli S, Söderström H, Nordh J, Bröjer C, Lindberg RH, Latorre-Margalef N, Waldenström J, Olsen B, Järhult JD. PLoS ONE 8 e71230 (2013)
  111. The conformational analysis and proton transfer of neuraminidase inhibitors: a theoretical study. Yang Z, Yang G, Zu Y, Fu Y, Zhou L. Phys Chem Chem Phys 11 10035-10041 (2009)
  112. Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus. Wang SQ, Cheng XC, Dong WL, Wang RL, Chou KC. Biochem. Biophys. Res. Commun. 401 188-191 (2010)
  113. Exploring the mechanism of zanamivir resistance in a neuraminidase mutant: a molecular dynamics study. Han N, Liu X, Mu Y. PLoS ONE 7 e44057 (2012)
  114. Homology modeling, docking, and molecular dynamics reveal HR1039 as a potent inhibitor of 2009 A(H1N1) influenza neuraminidase. Wang YT, Chan CH, Su ZY, Chen CL. Biophys. Chem. 147 74-80 (2010)
  115. Identification of critical residues of influenza neuraminidase in viral particle release. Tisoncik JR, Guo Y, Cordero KS, Yu J, Wang J, Cao Y, Rong L. Virol. J. 8 14 (2011)
  116. Inhibitory potency of flavonoid derivatives on influenza virus neuraminidase. Rakers C, Schwerdtfeger SM, Mortier J, Duwe S, Wolff T, Wolber G, Melzig MF. Bioorg. Med. Chem. Lett. 24 4312-4317 (2014)
  117. Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations. Pan P, Li L, Li Y, Li D, Hou T. Antiviral Res. 100 356-364 (2013)
  118. Mesoscale All-Atom Influenza Virus Simulations Suggest New Substrate Binding Mechanism. Durrant JD, Kochanek SE, Casalino L, Ieong PU, Dommer AC, Amaro RE. ACS Cent Sci 6 189-196 (2020)
  119. The neuraminidase of bat influenza viruses is not a neuraminidase. García-Sastre A. Proc. Natl. Acad. Sci. U.S.A. 109 18635-18636 (2012)
  120. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV). Mihajlovic ML, Mitrasinovic PM. Biophys. Chem. 136 152-158 (2008)
  121. Evolution and Divergence of H3N8 Equine Influenza Viruses Circulating in the United Kingdom from 2013 to 2015. Rash A, Morton R, Woodward A, Maes O, McCauley J, Bryant N, Elton D. Pathogens 6 (2017)
  122. Evolutionary dynamics of the N1 neuraminidases of the main lineages of influenza A viruses. Fourment M, Wood JT, Gibbs AJ, Gibbs MJ. Mol. Phylogenet. Evol. 56 526-535 (2010)
  123. Imaging of influenza virus sialidase activity in living cells. Kurebayashi Y, Takahashi T, Otsubo T, Ikeda K, Takahashi S, Takano M, Agarikuchi T, Sato T, Matsuda Y, Minami A, Kanazawa H, Uchida Y, Saito T, Kawaoka Y, Yamada T, Kawamori F, Thomson R, von Itzstein M, Suzuki T. Sci Rep 4 4877 (2014)
  124. Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity. von Grafenstein S, Wallnoefer HG, Kirchmair J, Fuchs JE, Huber RG, Schmidtke M, Sauerbrei A, Rollinger JM, Liedl KR. J. Biomol. Struct. Dyn. 33 104-120 (2015)
  125. Microsecond Molecular Dynamics Simulations of Influenza Neuraminidase Suggest a Mechanism for the Increased Virulence of Stalk-Deletion Mutants. Durrant JD, Bush RM, Amaro RE. J Phys Chem B 120 8590-8599 (2016)
  126. Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study. Yang Z, Yang G, Zhou L. J. Comput. Aided Mol. Des. 27 935-950 (2013)
  127. NA proteins of influenza A viruses H1N1/2009, H5N1, and H9N2 show differential effects on infection initiation, virus release, and cell-cell fusion. Chen Q, Huang S, Chen J, Zhang S, Chen Z. PLoS ONE 8 e54334 (2013)
  128. Oseltamivir-resistant influenza A(H1N1) viruses in south of France, 2007/2009. Casalegno JS, Bouscambert-Duchamp M, Caro V, Schuffenecker I, Sabatier M, Traversier A, Valette M, Lina B, Ferraris O, Escuret V. Antiviral Res. 87 242-248 (2010)
  129. Structural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289K. Tran-To Su C, Ouyang X, Zheng J, Kwoh CK. BMC Bioinformatics 14 Suppl 16 S7 (2013)
  130. Structural studies on the Pseudomonas aeruginosa sialidase-like enzyme PA2794 suggest substrate and mechanistic variations. Xu G, Ryan C, Kiefel MJ, Wilson JC, Taylor GL. J. Mol. Biol. 386 828-840 (2009)
  131. Structure and receptor binding specificity of hemagglutinin H13 from avian influenza A virus H13N6. Lu X, Qi J, Shi Y, Wang M, Smith DF, Heimburg-Molinaro J, Zhang Y, Paulson JC, Xiao H, Gao GF. J. Virol. 87 9077-9085 (2013)
  132. Symmetry-based design for the chemoenzymatic synthesis of oseltamivir (Tamiflu) from ethyl benzoate. Sullivan B, Carrera I, Drouin M, Hudlicky T. Angew. Chem. Int. Ed. Engl. 48 4229-4231 (2009)
  133. Synthesis of C-4-modified zanamivir analogs as neuraminidase inhibitors and their anti-AIV activities. Ye D, Shin WJ, Li N, Tang W, Feng E, Li J, He PL, Zuo JP, Kim H, Nam KY, Zhu W, Seong BL, No KT, Jiang H, Liu H. Eur J Med Chem 54 764-770 (2012)
  134. A 3D-RISM/RISM study of the oseltamivir binding efficiency with the wild-type and resistance-associated mutant forms of the viral influenza B neuraminidase. Phanich J, Rungrotmongkol T, Sindhikara D, Phongphanphanee S, Yoshida N, Hirata F, Kungwan N, Hannongbua S. Protein Sci. 25 147-158 (2016)
  135. A unique influenza A (H5N1) virus causing a focal poultry outbreak in 2007 in Manipur, India. Mishra AC, Cherian SS, Chakrabarti AK, Pawar SD, Jadhav SM, Pal B, Raut S, Koratkar S, Kode SS. Virol. J. 6 26 (2009)
  136. A virtual screening approach for identifying plants with anti H5N1 neuraminidase activity. Ikram NK, Durrant JD, Muchtaridi M, Zalaludin AS, Purwitasari N, Mohamed N, Rahim AS, Lam CK, Normi YM, Rahman NA, Amaro RE, Wahab HA. J Chem Inf Model 55 308-316 (2015)
  137. Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase. Ghosh A, Nandy A, Nandy P. BMC Struct. Biol. 10 6 (2010)
  138. Computer-guided approach to access the anti-influenza activity of licorice constituents. Grienke U, Braun H, Seidel N, Kirchmair J, Richter M, Krumbholz A, von Grafenstein S, Liedl KR, Schmidtke M, Rollinger JM. J. Nat. Prod. 77 563-570 (2014)
  139. In silico study on multidrug resistance conferred by I223R/H275Y double mutant neuraminidase. Tan H, Wei K, Bao J, Zhou X. Mol Biosyst 9 2764-2774 (2013)
  140. Intramolecular ion-pair prodrugs of zanamivir and guanidino-oseltamivir. Liu KC, Lee PS, Wang SY, Cheng YS, Fang JM, Wong CH. Bioorg. Med. Chem. 19 4796-4802 (2011)
  141. Molecular dynamics simulation of oseltamivir resistance in neuraminidase of avian influenza H5N1 virus. Shu M, Lin Z, Zhang Y, Wu Y, Mei H, Jiang Y. J Mol Model 17 587-592 (2011)
  142. Neuraminidase of Influenza A Virus Binds Lysosome-Associated Membrane Proteins Directly and Induces Lysosome Rupture. Ju X, Yan Y, Liu Q, Li N, Sheng M, Zhang L, Li X, Liang Z, Huang F, Liu K, Zhao Y, Zhang Y, Zou Z, Du J, Zhong Y, Zhou H, Yang P, Lu H, Tian M, Li D, Zhang J, Jin N, Jiang C. J. Virol. 89 10347-10358 (2015)
  143. Outside-binding site mutations modify the active site's shapes in neuraminidase from influenza A H1N1. Tolentino-Lopez L, Segura-Cabrera A, Reyes-Loyola P, Zimic M, Quiliano M, Briz V, Muñoz-Fernández A, Rodríguez-Pérez M, Ilizaliturri-Flores I, Correa-Basurto J. Biopolymers 99 10-21 (2013)
  144. Plasticity of 150-loop in influenza neuraminidase explored by Hamiltonian replica exchange molecular dynamics simulations. Han N, Mu Y. PLoS ONE 8 e60995 (2013)
  145. Potential drug-like inhibitors of Group 1 influenza neuraminidase identified through computer-aided drug design. Durrant JD, McCammon JA. Comput Biol Chem 34 97-105 (2010)
  146. Serendipitous discovery of a potent influenza virus a neuraminidase inhibitor. Mohan S, Kerry PS, Bance N, Niikura M, Pinto BM. Angew. Chem. Int. Ed. Engl. 53 1076-1080 (2014)
  147. Structure of influenza virus N7: the last piece of the neuraminidase "jigsaw" puzzle. Sun X, Li Q, Wu Y, Wang M, Liu Y, Qi J, Vavricka CJ, Gao GF. J. Virol. 88 9197-9207 (2014)
  148. Synthesis and evaluation of novel 3-C-alkylated-Neu5Ac2en derivatives as probes of influenza virus sialidase 150-loop flexibility. Rudrawar S, Kerry PS, Rameix-Welti MA, Maggioni A, Dyason JC, Rose FJ, van der Werf S, Thomson RJ, Naffakh N, Russell RJ, von Itzstein M. Org. Biomol. Chem. 10 8628-8639 (2012)
  149. Synthesis of acylguanidine zanamivir derivatives as neuraminidase inhibitors and the evaluation of their bio-activities. Lin CH, Chang TC, Das A, Fang MY, Hung HC, Hsu KC, Yang JM, von Itzstein M, Mong KK, Hsu TA, Lin CC. Org. Biomol. Chem. 11 3943-3948 (2013)
  150. A novel I221L substitution in neuraminidase confers high-level resistance to oseltamivir in influenza B viruses. Escuret V, Collins PJ, Casalegno JS, Vachieri SG, Cattle N, Ferraris O, Sabatier M, Frobert E, Caro V, Skehel JJ, Gamblin S, Valla F, Valette M, Ottmann M, McCauley JW, Daniels RS, Lina B. J. Infect. Dis. 210 1260-1269 (2014)
  151. Adaptive Heterosubtypic Immunity to Low Pathogenic Avian Influenza Viruses in Experimentally Infected Mallards. Segovia KM, Stallknecht DE, Kapczynski DR, Stabler L, Berghaus RD, Fotjik A, Latorre-Margalef N, França MS. PLoS ONE 12 e0170335 (2017)
  152. Alterations in hemagglutinin receptor-binding specificity accompany the emergence of highly pathogenic avian influenza viruses. Heider A, Mochalova L, Harder T, Tuzikov A, Bovin N, Wolff T, Matrosovich M, Schweiger B. J. Virol. 89 5395-5405 (2015)
  153. Catechin inhibition of influenza neuraminidase and its molecular basis with mass spectrometry. Müller P, Downard KM. J Pharm Biomed Anal 111 222-230 (2015)
  154. Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus. Park JW, Jo WH. Eur J Med Chem 45 536-541 (2010)
  155. Effects of Biomolecular Flexibility on Alchemical Calculations of Absolute Binding Free Energies. Lawrenz M, Baron R, Wang Y, McCammon JA. J Chem Theory Comput 7 2224-2232 (2011)
  156. In silico analysis of drug-resistant mutant of neuraminidase (N294S) against oseltamivir. Karthick V, Shanthi V, Rajasekaran R, Ramanathan K. Protoplasma 250 197-207 (2013)
  157. Insight into the oseltamivir resistance R292K mutation in H5N1 influenza virus: a molecular docking and molecular dynamics approach. Karthick V, Ramanathan K. Cell Biochem. Biophys. 68 291-299 (2014)
  158. Molecular mechanism of the enhanced viral fitness contributed by secondary mutations in the hemagglutinin protein of oseltamivir resistant H1N1 influenza viruses: modeling studies of antibody and receptor binding. Behera AK, Basu S, Cherian SS. Gene 557 19-27 (2015)
  159. Multistructural hot spot characterization with FTProd. Votapka L, Amaro RE. Bioinformatics 29 393-394 (2013)
  160. Neuraminidase-mediated haemagglutination of recent human influenza A(H3N2) viruses is determined by arginine 150 flanking the neuraminidase catalytic site. Mögling R, Richard MJ, Vliet SV, Beek RV, Schrauwen EJA, Spronken MI, Rimmelzwaan GF, Fouchier RAM. J. Gen. Virol. 98 1274-1281 (2017)
  161. Susceptibility of avian influenza viruses of the N6 subtype to the neuraminidase inhibitor oseltamivir. Stoner TD, Krauss S, Turner JC, Seiler P, Negovetich NJ, Stallknecht DE, Frase S, Govorkova EA, Webster RG. Antiviral Res. 93 322-329 (2012)
  162. Synthesizing non-natural parts from natural genomic template. Dhar PK, Thwin CS, Tun K, Tsumoto Y, Maurer-Stroh S, Eisenhaber F, Surana U. J Biol Eng 3 2 (2009)
  163. Letter Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)? Yu K, Luo C, Qin G, Xu Z, Li N, Liu H, Shen X, Ma J, Wang Q, Yang C, Zhu W, Jiang H. Cell Res. 19 1221-1224 (2009)
  164. Why does avian influenza A virus hemagglutinin bind to avian receptor stronger than to human receptor? Ab initio fragment molecular orbital studies. Sawada T, Hashimoto T, Nakano H, Suzuki T, Ishida H, Kiso M. Biochem. Biophys. Res. Commun. 351 40-43 (2006)
  165. Aglycone-focused randomization of 2-difluoromethylphenyl-type sialoside suicide substrates for neuraminidases. Kai H, Hinou H, Nishimura S. Bioorg. Med. Chem. 20 2739-2746 (2012)
  166. BDflex: a method for efficient treatment of molecular flexibility in calculating protein-ligand binding rate constants from brownian dynamics simulations. Greives N, Zhou HX. J Chem Phys 137 135105 (2012)
  167. Computer-based de novo designs of tripeptides as novel neuraminidase inhibitors. Yang Z, Yang G, Zu Y, Fu Y, Zhou L. Int J Mol Sci 11 4932-4951 (2010)
  168. Identification of Residues That Affect Oligomerization and/or Enzymatic Activity of Influenza Virus H5N1 Neuraminidase Proteins. Dai M, Guo H, Dortmans JC, Dekkers J, Nordholm J, Daniels R, van Kuppeveld FJ, de Vries E, de Haan CA. J. Virol. 90 9457-9470 (2016)
  169. Comment Implications of antiviral resistance of influenza viruses. Monto AS. Clin. Infect. Dis. 48 397-399 (2009)
  170. Inhibition of neuraminidase by Ganoderma triterpenoids and implications for neuraminidase inhibitor design. Zhu Q, Bang TH, Ohnuki K, Sawai T, Sawai K, Shimizu K. Sci Rep 5 13194 (2015)
  171. Organization of influenza A virus envelope at neutral and low pH. Giocondi MC, Ronzon F, Nicolai MC, Dosset P, Milhiet PE, Chevalier M, Le Grimellec C. J. Gen. Virol. 91 329-338 (2010)
  172. Parallel screening of wild-type and drug-resistant targets for anti-resistance neuraminidase inhibitors. Hsu KC, Hung HC, Horng JT, Fang MY, Chang CY, Li LT, Chen IJ, Chen YC, Chou DL, Chang CW, Hsieh HP, Yang JM, Hsu JT. PLoS ONE 8 e56704 (2013)
  173. Quantitative predictions of binding free energy changes in drug-resistant influenza neuraminidase. Ripoll DR, Khavrutskii IV, Chaudhury S, Liu J, Kuschner RA, Wallqvist A, Reifman J. PLoS Comput. Biol. 8 e1002665 (2012)
  174. Replication inhibition activity of carbocycles related to oseltamivir on influenza A virus in vitro. Niikura M, Bance N, Mohan S, Mario Pinto B. Antiviral Res. 90 160-163 (2011)
  175. Structural and functional analysis of surface proteins from an A(H3N8) influenza virus isolated from New England harbor seals. Yang H, Nguyen HT, Carney PJ, Guo Z, Chang JC, Jones J, Davis CT, Villanueva JM, Gubareva LV, Stevens J. J. Virol. 89 2801-2812 (2015)
  176. Study of oseltamivir and zanamivir resistance-related mutations in influenza viruses isolated from wild mallards in Sweden. Orozovic G, Orozovic K, Järhult JD, Olsen B. PLoS ONE 9 e89306 (2014)
  177. Synthesis and in vitro study of novel neuraminidase inhibitors against avian influenza virus. Kongkamnerd J, Cappelletti L, Prandi A, Seneci P, Rungrotmongkol T, Jongaroonngamsang N, Rojsitthisak P, Frecer V, Milani A, Cattoli G, Terregino C, Capua I, Beneduce L, Gallotta A, Pengo P, Fassina G, Miertus S, De-Eknamkul W. Bioorg. Med. Chem. 20 2152-2157 (2012)
  178. The binding properties of the H5N1 influenza virus neuraminidase as inferred from molecular modeling. Raab M, Tvaroška I. J Mol Model 17 1445-1456 (2011)
  179. The breadth of cross sub-type neutralisation activity of a single domain antibody to influenza hemagglutinin can be increased by antibody valency. Hufton SE, Risley P, Ball CR, Major D, Engelhardt OG, Poole S. PLoS ONE 9 e103294 (2014)
  180. The nonadaptive nature of the H1N1 2009 Swine Flu pandemic contrasts with the adaptive facilitation of transmission to a new host. Abdussamad J, Aris-Brosou S. BMC Evol. Biol. 11 6 (2011)
  181. The use of glycoinformatics in glycochemistry. Lütteke T. Beilstein J Org Chem 8 915-929 (2012)
  182. A proline-based neuraminidase inhibitor: DFT studies on the zwitterion conformation, stability and formation. Yang ZW, Wu XM, Zhou LJ, Yang G. Int J Mol Sci 10 3918-3930 (2009)
  183. A screening assay for neuraminidase inhibitors using neuraminidases N1 and N3 from a baculovirus expression system. Kongkamnerd J, Milani A, Cattoli G, Terregino C, Capua I, Beneduce L, Gallotta A, Pengo P, Fassina G, Miertus S, De-Eknamkul W. J Enzyme Inhib Med Chem 27 5-11 (2012)
  184. Amino acid determinants conferring stable sialidase activity at low pH for H5N1 influenza A virus neuraminidase. Takahashi T, Nidom CA, Quynh Le MT, Suzuki T, Kawaoka Y. FEBS Open Bio 2 261-266 (2012)
  185. Biased mutational pattern and quasispecies hypothesis in H5N1 virus. Gutiérrez RA, Viari A, Godelle B, Frutos R, Buchy P. Infect. Genet. Evol. 15 69-76 (2013)
  186. Characterization of human H1N1 influenza virus variants selected in vitro with zanamivir in the presence of sialic acid-containing molecules. Giannecchini S, Campitelli L, Bandini G, Donatelli I, Azzi A. Virus Res. 129 241-245 (2007)
  187. Discovery of a new sesquiterpenoid from Phellinus ignarius with antiviral activity against influenza virus. Song AR, Sun XL, Kong C, Zhao C, Qin D, Huang F, Yang S. Arch. Virol. 159 753-760 (2014)
  188. Evaluation of the antigenic relatedness and cross-protective immunity of the neuraminidase between human influenza A (H1N1) virus and highly pathogenic avian influenza A (H5N1) virus. Lu X, Liu F, Zeng H, Sheu T, Achenbach JE, Veguilla V, Gubareva LV, Garten R, Smith C, Yang H, Stevens J, Xu X, Katz JM, Tumpey TM. Virology 454-455 169-175 (2014)
  189. Evolution of complementary nucleotides in 5' and 3' untranslated regions of influenza A virus genomic segments. Suzuki Y, Kobayashi Y. Infect. Genet. Evol. 13 175-179 (2013)
  190. Exploring the molecular basis of dsRNA recognition by NS1 protein of influenza A virus using molecular dynamics simulation and free energy calculation. Pan D, Sun H, Shen Y, Liu H, Yao X. Antiviral Res. 92 424-433 (2011)
  191. Identification and characterization of sialidase-like activity in the developmental stages of Amblyomma variegatum. Natala AJ, Balogun EO, Balogun JA, Inuwa HM, Nok AJ, Shiba T, Harada S, Kita K, Agbede RI, Esievo KA. J. Med. Entomol. 50 85-93 (2013)
  192. Identification of novel compounds against an R294K substitution of influenza A (H7N9) virus using ensemble based drug virtual screening. Tran N, Van T, Nguyen H, Le L. Int J Med Sci 12 163-176 (2015)
  193. Neuraminidase inhibition of Dietary chlorogenic acids and derivatives - potential antivirals from dietary sources. Gamaleldin Elsadig Karar M, Matei MF, Jaiswal R, Illenberger S, Kuhnert N. Food Funct 7 2052-2059 (2016)
  194. Optimization of a direct spectrophotometric method to investigate the kinetics and inhibition of sialidases. Hayre JK, Xu G, Borgianni L, Taylor GL, Andrew PW, Docquier JD, Oggioni MR. BMC Biochem. 13 19 (2012)
  195. Pyrosequencing reveals an oseltamivir-resistant marker in the quasispecies of avian influenza A (H7N9) virus. Mok CK, Chang SC, Chen GW, Lo YL, Chen SJ, Wu HS, Liu MT, Chang FY, Lin TY, Shih SR. J Microbiol Immunol Infect 48 465-469 (2015)
  196. Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study. Phanich J, Rungrotmongkol T, Kungwan N, Hannongbua S. J. Comput. Aided Mol. Des. 30 917-926 (2016)
  197. Sequence diversity of NanA manifests in distinct enzyme kinetics and inhibitor susceptibility. Xu Z, von Grafenstein S, Walther E, Fuchs JE, Liedl KR, Sauerbrei A, Schmidtke M. Sci Rep 6 25169 (2016)
  198. Sialivac: an intranasal homologous inactivated split virus vaccine containing bacterial sialidase for the control of avian influenza in poultry. Worrall EE, Sudarisman, Priadi A. Vaccine 27 4161-4168 (2009)
  199. Survival analysis of infected mice reveals pathogenic variations in the genome of avian H1N1 viruses. Koçer ZA, Fan Y, Huether R, Obenauer J, Webby RJ, Zhang J, Webster RG, Wu G. Sci Rep 4 7455 (2014)
  200. Synthesis of selective inhibitors against V. cholerae sialidase and human cytosolic sialidase NEU2. Khedri Z, Li Y, Cao H, Qu J, Yu H, Muthana MM, Chen X. Org. Biomol. Chem. 10 6112-6120 (2012)
  201. Tamiphosphor monoesters as effective anti-influenza agents. Chen CL, Lin TC, Wang SY, Shie JJ, Tsai KC, Cheng YS, Jan JT, Lin CJ, Fang JM, Wong CH. Eur J Med Chem 81 106-118 (2014)
  202. Assessment of Molecular, Antigenic, and Pathological Features of Canine Influenza A(H3N2) Viruses That Emerged in the United States. Pulit-Penaloza JA, Simpson N, Yang H, Creager HM, Jones J, Carney P, Belser JA, Yang G, Chang J, Zeng H, Thor S, Jang Y, Killian ML, Jenkins-Moore M, Janas-Martindale A, Dubovi E, Wentworth DE, Stevens J, Tumpey TM, Davis CT, Maines TR. J. Infect. Dis. 216 S499-S507 (2017)
  203. Bifunctional thiosialosides inhibit influenza virus. Yang Y, He Y, Li X, Dinh H, Iyer SS. Bioorg. Med. Chem. Lett. 24 636-643 (2014)
  204. Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models. Lian W, Fang J, Li C, Pang X, Liu AL, Du GH. Mol. Divers. 20 439-451 (2016)
  205. Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins. Gubareva LV, Sleeman K, Guo Z, Yang H, Hodges E, Davis CT, Baranovich T, Stevens J. J. Infect. Dis. 216 S566-S574 (2017)
  206. Extraction of catalytically active neuraminidase of H5N1 influenza virus using thrombin proteolytic cleavage. Wanitchang A, Wongwisarnsri S, Yongkiettrakul S, Jongkaewwattana A. J. Virol. Methods 163 137-143 (2010)
  207. Genetic characterization of two low pathogenic avian influenza virus H5N1 isolates from Ontario, Canada. Pei Y, Swinton J, Ojkic D, Sharif S. Virus Genes 38 149-154 (2009)
  208. Grid-enabled high-throughput in silico screening against influenza A neuraminidase. Lee HC, Salzemann J, Jacq N, Chen HY, Ho LY, Merelli I, Milanesi L, Breton V, Lin SC, Wu YT. IEEE Trans Nanobioscience 5 288-295 (2006)
  209. Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9). Gaymard A, Charles-Dufant A, Sabatier M, Cortay JC, Frobert E, Picard C, Casalegno JS, Rosa-Calatrava M, Ferraris O, Valette M, Ottmann M, Lina B, Escuret V. J. Antimicrob. Chemother. 71 3036-3045 (2016)
  210. Oseltamivir Resistance in Influenza A(H6N2) Caused by an R292K Substitution in Neuraminidase Is Not Maintained in Mallards without Drug Pressure. Gillman A, Muradrasoli S, Mårdnäs A, Söderström H, Fedorova G, Löwenthal M, Wille M, Daggfeldt A, Järhult JD. PLoS ONE 10 e0139415 (2015)
  211. Probing molecular level interaction of oseltamivir with H5N1-NA and model membranes by molecular docking, multinuclear NMR and DSC methods. D'Souza C, Kanyalkar M, Joshi M, Coutinho E, Srivastava S. Biochim. Biophys. Acta 1788 484-494 (2009)
  212. Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor. Wu Y, Gao F, Qi J, Bi Y, Fu L, Mohan S, Chen Y, Li X, Pinto BM, Vavricka CJ, Tien P, Gao GF. J. Virol. 90 10693-10700 (2016)
  213. Studies on synthesis and structure-activity relationship (SAR) of derivatives of a new natural product from marine fungi as inhibitors of influenza virus neuraminidase. Li J, Zhang D, Zhu X, He Z, Liu S, Li M, Pang J, Lin Y. Mar Drugs 9 1887-1901 (2011)
  214. Substituent effects on the binding of natural product anthocyanidin inhibitors to influenza neuraminidase with mass spectrometry. Swaminathan K, Müller P, Downard KM. Anal. Chim. Acta 828 61-69 (2014)
  215. 3D Molecular Modelling Study of the H7N9 RNA-Dependent RNA Polymerase as an Emerging Pharmacological Target. Vlachakis D, Karozou A, Kossida S. Influenza Res Treat 2013 645348 (2013)
  216. A Screening of Neuraminidase Inhibition Activities of Isoquinolone Alkaloids in Coptis chinensis Using Molecular Docking and Pharmacophore Analysis. Le K, Tran D, Nguyen A, Le L. ACS Omega 5 30315-30322 (2020)
  217. A dual-functional molecular strategy for in situ suppressing and visualizing of neuraminidase in aqueous solution using iridium(iii) complexes. Wu C, Wu KJ, Liu JB, Zhou XM, Leung CH, Ma DL. Chem Commun (Camb) 55 6353-6356 (2019)
  218. A strategy for neuraminidase inhibitors using mechanism-based labeling information. Hinou H, Miyoshi R, Takasu Y, Kai H, Kurogochi M, Arioka S, Gao XD, Miura N, Fujitani N, Omoto S, Yoshinaga T, Fujiwara T, Noshi T, Togame H, Takemoto H, Nishimura S. Chem Asian J 6 1048-1056 (2011)
  219. An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness. Kwon JJ, Choi WS, Jeong JH, Kim EH, Lee OJ, Yoon SW, Hwang J, Webby RJ, Govorkova EA, Choi YK, Baek YH, Song MS. J. Gen. Virol. 99 292-302 (2018)
  220. Co-evolution analysis to predict protein-protein interactions within influenza virus envelope. Mintaev RR, Alexeevski AV, Kordyukova LV. J Bioinform Comput Biol 12 1441008 (2014)
  221. Letter Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)". Rungrotmongkol T, Malaisree M, Udommaneethanakit T, Hannongbua S. Biophys. Chem. 141 131-2; author reply 133 (2009)
  222. Crystal structure of a new benzoic acid inhibitor of influenza neuraminidase bound with a new tilt induced by overpacking subsite C6. Venkatramani L, Johnson ES, Kolavi G, Air GM, Brouillette WJ, Mooers BH. BMC Struct. Biol. 12 7 (2012)
  223. Design of multiligand inhibitors for the swine flu H1N1 neuraminidase binding site. Narayanan MM, Nair CB, Sanjeeva SK, Rao PS, Pullela PK, Barrow CJ. Adv Appl Bioinform Chem 6 47-53 (2013)
  224. Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors. Liu Y, Zhang L, Gong J, Fang H, Liu A, Du G, Xu W. J Enzyme Inhib Med Chem 26 506-513 (2011)
  225. Discovery and Characterization of Diazenylaryl Sulfonic Acids as Inhibitors of Viral and Bacterial Neuraminidases. Hoffmann A, Richter M, von Grafenstein S, Walther E, Xu Z, Schumann L, Grienke U, Mair CE, Kramer C, Rollinger JM, Liedl KR, Schmidtke M, Kirchmair J. Front Microbiol 8 205 (2017)
  226. Double-Layered M2e-NA Protein Nanoparticle Immunization Induces Broad Cross-Protection against Different Influenza Viruses in Mice. Wang Y, Deng L, Gonzalez GX, Luthra L, Dong C, Ma Y, Zou J, Kang SM, Wang BZ. Adv Healthc Mater 9 e1901176 (2020)
  227. Five Novel Non-Sialic Acid-Like Scaffolds Inhibit In Vitro H1N1 and H5N2 Neuraminidase Activity of Influenza a Virus. Márquez-Domínguez L, Reyes-Leyva J, Herrera-Camacho I, Santos-López G, Scior T. Molecules 25 E4248 (2020)
  228. Glycan based detection and drug susceptibility of influenza virus. Dinh H, Zhang X, Sweeney J, Yang Y, He Y, Dhawane A, Iyer SS. Anal. Chem. 86 8238-8244 (2014)
  229. Highly pathogenic avian influenza virus subtype H5N1 in mute swans (Cygnus olor) in Central Bosnia. Goletić T, Gagić A, Residbegović E, Kustura A, Kavazović A, Savić V, Harder T, Starick E, Prasović S. Avian Dis. 54 496-501 (2010)
  230. Mass spectrometry analysis of influenza virus reassortant clones does not reveal an influence of other viral proteins on S-acylation of hemagglutinin. Serebryakova MV, Kordyukova LV, Rudneva IA, Kropotkina EA, Veit M, Baratova LA. Arch. Virol. 158 467-472 (2013)
  231. Progress in structure-based drug design against influenza A virus. Du QS, Wei H, Huang RB, Chou KC. Expert Opin Drug Discov 6 619-631 (2011)
  232. Quantitative structural analysis of influenza virus by cryo-electron tomography and convolutional neural networks. Huang QJ, Song K, Xu C, Bolon DNA, Wang JP, Finberg RW, Schiffer CA, Somasundaran M. Structure 30 777-786.e3 (2022)
  233. Screening for Neuraminidase Inhibitor Resistance Markers among Avian Influenza Viruses of the N4, N5, N6, and N8 Neuraminidase Subtypes. Choi WS, Jeong JH, Kwon JJ, Ahn SJ, Lloren KKS, Kwon HI, Chae HB, Hwang J, Kim MH, Kim CJ, Webby RJ, Govorkova EA, Choi YK, Baek YH, Song MS. J. Virol. 92 (2018)
  234. Synthesis and evaluation of influenza A viral neuraminidase candidate inhibitors based on a bicyclo[3.1.0]hexane scaffold. Colombo C, Pinto BM, Bernardi A, Bennet AJ. Org. Biomol. Chem. 14 6539-6553 (2016)
  235. Synthesis, structure and inhibitory activity of a stereoisomer of oseltamivir carboxylate. Sartori A, Dell'Amico L, Battistini L, Curti C, Rivara S, Pala D, Kerry PS, Pelosi G, Casiraghi G, Rassu G, Zanardi F. Org. Biomol. Chem. 12 1561-1569 (2014)
  236. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses. Singh A, Soliman ME. Drug Des Devel Ther 9 4137-4154 (2015)
  237. Viral fusion efficacy of specific H3N2 influenza virus reassortant combinations at single-particle level. Hsu HL, Millet JK, Costello DA, Whittaker GR, Daniel S. Sci Rep 6 35537 (2016)
  238. Virtual screening for oseltamivir-resistant a (H5N1) influenza neuraminidase from traditional Chinese medicine database: a combined molecular docking with molecular dynamics approach. Karthick V, Ramanathan K. Springerplus 2 115 (2013)
  239. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase. D'Ursi P, Chiappori F, Merelli I, Cozzi P, Rovida E, Milanesi L. Biochem. Biophys. Res. Commun. 383 445-449 (2009)
  240. Analysis of oseltamivir resistance substitutions in influenza virus glycoprotein neuraminidase using a lentivirus-based surrogate assay system. Tisoncik-Go J, Cordero KS, Rong L. Virol Sin 28 81-91 (2013)
  241. Bioinformatic analysis of subfamily-specific regions in 3D-structures of homologs to study functional diversity and conformational plasticity in protein superfamilies. Timonina D, Sharapova Y, Švedas V, Suplatov D. Comput Struct Biotechnol J 19 1302-1311 (2021)
  242. Computable features required to evaluate the efficacy of drugs and a universal algorithm to find optimally effective drug in a drug complex. Wang K, Cui W, Hu G, Gao J, Wu Z, Qiu X, Ruan J, Feng Y, Qi Z, Shao Y, Tuszynski JA. PLoS ONE 7 e33709 (2012)
  243. Further discovery of caffeic acid derivatives as novel influenza neuraminidase inhibitors. Xie Y, Huang B, Yu K, Xu W. Bioorg. Med. Chem. 21 7715-7723 (2013)
  244. Highly specific and rapid glycan based amperometric detection of influenza viruses. Cui X, Das A, Dhawane AN, Sweeney J, Zhang X, Chivukula V, Iyer SS. Chem Sci 8 3628-3634 (2017)
  245. Identification and characterization of novel small-molecule inhibitors against hepatitis delta virus replication by using docking strategies. Singh S, Gupta SK, Nischal A, Khattri S, Nath R, Pant KK, Seth PK. Hepat Mon 11 803-809 (2011)
  246. In-silico structural analysis of the influenza A subtype H7N9 neuraminidase and molecular docking with different neuraminidase inhibitors. Eweas AF, Abdel-Moneim AS. Virusdisease 26 27-32 (2015)
  247. Inhibition of viral group-1 and group-2 neuraminidases by oseltamivir: A comparative structural analysis by the ScrewFit algorithm. Calligari PA, Kneller GR, Giansanti A, Ascenzi P, Porrello A, Bocedi A. Biophys. Chem. 141 117-123 (2009)
  248. Kinetic, thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) pandemic influenza. Albiñana CB, Machara A, Řezáčová P, Pachl P, Konvalinka J, Kožíšek M. Eur J Med Chem 121 100-109 (2016)
  249. Molecular dynamics directed CoMFA studies on carbocyclic neuraminidase inhibitors. Chavan S, Bhayye S, Sobhia ME. Mol. Divers. 15 979-987 (2011)
  250. Neuraminidase amino acids 149 and 347 determine the infectivity and oseltamivir sensitivity of pandemic influenza A/H1N1 (2009) and avian influenza A/H5N1. Yongkiettrakul S, Nivitchanyong T, Pannengpetch S, Wanitchang A, Jongkaewwattana A, Srimanote P. Virus Res. 175 128-133 (2013)
  251. Novel oral anti-influenza drug candidate AV5080. Ivachtchenko AV, Ivanenkov YA, Mitkin OD, Yamanushkin PM, Bichko VV, Shevkun NA, Karapetian RN, Leneva IA, Borisova OV, Veselov MS. J. Antimicrob. Chemother. 69 1892-1902 (2014)
  252. Polyphenolic glycosides isolated from Pogostemon cablin (Blanco) Benth. as novel influenza neuraminidase inhibitors. Liu F, Cao W, Deng C, Wu Z, Zeng G, Zhou Y. Chem Cent J 10 51 (2016)
  253. Pyrrolidinobenzoic acid inhibitors of influenza virus neuraminidase: the hydrophobic side chain influences type A subtype selectivity. Li Y, Silamkoti A, Kolavi G, Mou L, Gulati S, Air GM, Brouillette WJ. Bioorg. Med. Chem. 20 4582-4589 (2012)
  254. Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1. Li Y, Zhou B, Wang R. J. Mol. Graph. Model. 28 203-219 (2009)
  255. Reactivity of 12-tungstophosphoric acid and its inhibitor potency toward Na+/K+-ATPase: A combined 31P NMR study, ab initio calculations and crystallographic analysis. Bošnjaković-Pavlović N, Bajuk-Bogdanović D, Zakrzewska J, Yan Z, Holclajtner-Antunović I, Gillet JM, Spasojević-de Biré A. J. Inorg. Biochem. 176 90-99 (2017)
  256. Stereoisomers of oseltamivir - synthesis, in silico prediction and biological evaluation. Hajzer V, Fišera R, Latika A, Durmis J, Kollár J, Frecer V, Tučeková Z, Miertuš S, Kostolanský F, Varečková E, Šebesta R. Org. Biomol. Chem. 15 1828-1841 (2017)
  257. Surveillance for antiviral resistance. Zambon MC. Influenza Other Respir Viruses 7 Suppl 1 37-43 (2013)
  258. Synthesis of oseltamivir and tamiphosphor from N-acetyl-D-glucosamine. Chen CA, Fang JM. Org. Biomol. Chem. 11 7687-7699 (2013)
  259. The elusive crystal structure of the neuraminidase inhibitor Tamiflu (oseltamivir phosphate): molecular details of action. Naumov P, Yasuda N, Rabeh WM, Bernstein J. Chem. Commun. (Camb.) 49 1948-1950 (2013)
  260. The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern. Schaduangrat N, Phanich J, Rungrotmongkol T, Lerdsamran H, Puthavathana P, Ubol S. J. Gen. Virol. 97 1311-1323 (2016)
  261. Virtual screening approach to identifying influenza virus neuraminidase inhibitors using molecular docking combined with machine-learning-based scoring function. Zhang L, Ai HX, Li SM, Qi MY, Zhao J, Zhao Q, Liu HS. Oncotarget 8 83142-83154 (2017)
  262. Amino Acid-Based Synthesis and Glycosidase Inhibition of Cyclopropane-Containing Iminosugars. Puet A, Domínguez G, Cañada FJ, Pérez-Castells J. ACS Omega 5 31821-31830 (2020)
  263. Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means. Terrier O, Slama-Schwok A. Adv Exp Med Biol 1322 195-218 (2021)
  264. Anti-Influenza Virus (H5N1) Activity Screening on the Phloroglucinols from Rhizomes of Dryopteris crassirhizoma. Wang J, Yan YT, Fu SZ, Peng B, Bao LL, Zhang YL, Hu JH, Zeng ZP, Geng DH, Gao ZP. Molecules 22 (2017)
  265. Assessing the oseltamivir-induced resistance risk and implications for influenza infection control strategies. Hsieh NH, Lin YJ, Yang YF, Liao CM. Infect Drug Resist 10 215-226 (2017)
  266. Letter Atypical group 1 neuraminidase pH1N1-N1 bound to a group 1 inhibitor. Wu Y, Vavricka CJ, Wu Y, Li Q, Rudrawar S, Thomson RJ, von Itzstein M, Gao GF, Qi J. Protein Cell 6 771-773 (2015)
  267. CISAPS: Complex Informational Spectrum for the Analysis of Protein Sequences. Chrysostomou C, Seker H, Aydin N. Adv Bioinformatics 2015 909765 (2015)
  268. Characterization of the Cross-Species Transmission Potential for Porcine Deltacoronaviruses Expressing Sparrow Coronavirus Spike Protein in Commercial Poultry. Alhamo MA, Boley PA, Liu M, Niu X, Yadav KK, Lee C, Saif LJ, Wang Q, Kenney SP. Viruses 14 1225 (2022)
  269. Computational study on new natural polycyclic compounds of H1N1 influenza virus neuraminidase. Wang Y, Wu D, Yu D, Wang Z, Tian L, Wang Y, Han W, Fang X. J Mol Model 18 3445-3453 (2012)
  270. Design and synthesis of 1,2,3-triazole-containing N-acyl zanamivir analogs as potent neuraminidase inhibitors. Das A, Adak AK, Ponnapalli K, Lin CH, Hsu KC, Yang JM, Hsu TA, Lin CC. Eur J Med Chem 123 397-406 (2016)
  271. Design and synthesis of 6-oxo-1,4,5,6-tetrahydropyrimidine-5-carboxylate derivatives as neuraminidase inhibitors. Lou J, Yang X, Rao Z, Qi W, Li J, Wang H, Li Y, Li J, Wang Z, Hu X, Liu P, Hong X. Eur J Med Chem 83 466-473 (2014)
  272. Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase. Colombo C, Podlipnik Č, Lo Presti L, Niikura M, Bennet AJ, Bernardi A. PLoS ONE 13 e0193623 (2018)
  273. Design, Synthesis, and Biological Evaluation of Novel Acylhydrazone Derivatives as Potent Neuraminidase Inhibitors. Li M, Cheng LP, Pang W, Zhong ZJ, Guo LL. ACS Med Chem Lett 11 1745-1750 (2020)
  274. Effect of sesamin against cytokine production from influenza type A H1N1-induced peripheral blood mononuclear cells: computational and experimental studies. Fanhchaksai K, Kodchakorn K, Pothacharoen P, Kongtawelert P. In Vitro Cell. Dev. Biol. Anim. 52 107-119 (2016)
  275. Evaluation of a Set of C9 N-acyl Neu5Ac2en Mimetics as Viral Sialidase Selective Inhibitors. Magesh S, Sriwilaijaroen N, Moriya S, Ando H, Miyagi T, Suzuki Y, Ishida H, Kiso M. Int J Med Chem 2011 539245 (2011)
  276. Finite element analysis of drug electrostatic diffusion: inhibition rate studies in N1 neuraminidase. Cheng Y, Holst MJ, McCammon JA. Pac Symp Biocomput 281-292 (2009)
  277. Identification of Suitable Natural Inhibitor against Influenza A (H1N1) Neuraminidase Protein by Molecular Docking. Sahoo M, Jena L, Rath SN, Kumar S. Genomics Inform 14 96-103 (2016)
  278. Identification of neuraminidase inhibitors against dual H274Y/I222R mutant strains. Hsu KC, Hung HC, HuangFu WC, Sung TY, Eight Lin T, Fang MY, Chen IJ, Pathak N, Hsu JT, Yang JM. Sci Rep 7 12336 (2017)
  279. Identification of the 5'-Terminal Packaging Signal of the H1N1 Influenza A Virus Neuraminidase Segment at Single-Nucleotide Resolution. Seshimo E, Momose F, Morikawa Y. Front Microbiol 12 709010 (2021)
  280. In Silico Drug Repurposing of FDA-Approved Drugs Highlighting Promacta as a Potential Inhibitor of H7N9 Influenza Virus. Mtambo SE, Kumalo HM. Molecules 27 4515 (2022)
  281. Inhibition activity of a traditional Chinese herbal formula Huang-Lian-Jie-Du-Tang and its major components found in its plasma profile on neuraminidase-1. Zhou X, Li H, Shi Z, Gao S, Wei S, Li K, Wang J, Li J, Wang R, Gong M, Zhao Y, Xiao X. Sci Rep 7 15549 (2017)
  282. Insights from QM/MM Modeling the 3D Structure of the 2009 H1N1 Influenza A Virus Neuraminidase and Its Binding Interactions with Antiviral Drugs. Wang YT, Chen YC. Mol Inform 33 240-249 (2014)
  283. MARCH8 inhibits influenza A virus infection by targeting viral M2 protein for ubiquitination-dependent degradation in lysosomes. Liu X, Xu F, Ren L, Zhao F, Huang Y, Wei L, Wang Y, Wang C, Fan Z, Mei S, Song J, Zhao Z, Cen S, Liang C, Wang J, Guo F. Nat Commun 12 4427 (2021)
  284. Magnetic beads-based neuraminidase enzyme microreactor as a drug discovery tool for screening inhibitors from compound libraries and fishing ligands from natural products. Zhao YM, Wang LH, Luo SF, Wang QQ, Moaddel R, Zhang TT, Jiang ZJ. J Chromatogr A 1568 123-130 (2018)
  285. Molecular modeling and lead design of substituted zanamivir derivatives as potent anti-influenza drugs. Dholakia D, Goyal S, Jamal S, Singh A, Das A, Grover A. BMC Bioinformatics 17 512 (2016)
  286. Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza. Le L, Lee E, Schulten K, Truong TN. PLoS Curr 1 RRN1015 (2009)
  287. Novel 3,4-disubstituted-Neu5Ac2en derivatives as probes to investigate flexibility of the influenza virus sialidase 150-loop. Rudrawar S, Dyason JC, Maggioni A, Thomson RJ, von Itzstein M. Bioorg. Med. Chem. 21 4820-4830 (2013)
  288. Peptide-Based Antiviral Drugs. Murugan NA, Raja KMP, Saraswathi NT. Adv Exp Med Biol 1322 261-284 (2021)
  289. Promising Anti-influenza Properties of Active Constituent of Withania somnifera Ayurvedic Herb in Targeting Neuraminidase of H1N1 Influenza: Computational Study. Cai Z, Zhang G, Tang B, Liu Y, Fu X, Zhang X. Cell Biochem. Biophys. 72 727-739 (2015)
  290. Reconstruction of 3D density from solution scattering. Grant TD. Methods Enzymol 678 145-192 (2023)
  291. Substrate specificity of avian influenza H5N1 neuraminidase. Onsirisakul N, Nakakita S, Boonarkart C, Kongchanagul A, Suptawiwat O, Puthavathana P, Chaichuen K, Kittiniyom K, Suzuki Y, Auewarakul P. World J Virol 3 30-36 (2014)
  292. Targeting a cluster of arginine residues of neuraminidase to avoid oseltamivir resistance in influenza A (H1N1): a theoretical study. Gema LR, Tolentino-Lopez LE, Martínez-Ramos F, Padilla-Martínez I, García-Machorro J, Correa-Basurto J. J Mol Model 21 8 (2015)
  293. The Mechanism by which 146-N-Glycan Affects the Active Site of Neuraminidase. Liu P, Wang Z, Zhang L, Li D, Lin J. PLoS ONE 10 e0135487 (2015)
  294. Vaccine Design for H5N1 Based on B- and T-cell Epitope Predictions. Tambunan US, Sipahutar FR, Parikesit AA, Kerami D. Bioinform Biol Insights 10 27-35 (2016)
  295. Variable ligand- and receptor-binding hot spots in key strains of influenza neuraminidase. Votapka L, Demir O, Swift RV, Walker RC, Amaro RE. J Mol Genet Med 6 293-300 (2012)
  296. 2,5-Diketopiperazine Derivatives as Potential Anti-Influenza (H5N2) Agents: Synthesis, Biological Evaluation, and Molecular Docking Study. Winyakul C, Phutdhawong W, Tamdee P, Sirirak J, Taechowisan T, Phutdhawong WS. Molecules 27 4200 (2022)
  297. A novel N-heterocycles substituted oseltamivir derivatives as potent inhibitors of influenza virus neuraminidase: discovery, synthesis and biological evaluation. Zhang J, Liu C, Jia R, Zhang X, Zhang J, Bertagnin C, Bonomini A, Guizzo L, Jiang Y, Jia H, Jia S, Ma X, Loregian A, Huang B, Zhan P, Liu X. J Enzyme Inhib Med Chem 38 2277135 (2023)
  298. A study on catalytic and non-catalytic sites of H5N1 and H1N1 neuraminidase as the target for chalcone inhibitors. Hariyono P, Kotta JC, Adhipandito CF, Aprilianto E, Candaya EJ, Wahab HA, Hariono M. Appl Biol Chem 64 69 (2021)
  299. A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir. Somasundaram B, Fee CJ, Fredericks R, Watson AJ, Fairbanks AJ, Hall RJ. J. Mol. Recognit. 28 521-527 (2015)
  300. Antiviral Activity of Benzoic Acid Derivative NC-5 Against Influenza A Virus and Its Neuraminidase Inhibition. Guo M, Ni J, Yu J, Jin J, Ma L, Zhang H, Wang D, Zhang X, Dou J, Zhou C. Int J Mol Sci 20 (2019)
  301. Assessing compatibility and viral fitness between poultry-adapted H9N2 and wild bird-derived neuraminidases. Wasberg A, Faria IR, Bergholm J, Petric PP, Mostafa A, Pleschka S, Schwemmle M, Lundkvist Å, Ellström P, Naguib MM. Sci Rep 13 4476 (2023)
  302. Binding mechanism of oseltamivir and influenza neuraminidase suggests perspectives for the design of new anti-influenza drugs. Tao J, Wang H, Wang W, Mi N, Zhang W, Wen Q, Ouyang J, Liang X, Chen M, Guo W, Li G, Liu J, Zhao H, Wang X, Li X, Feng S, Liu X, He Z, Zhao Z. PLoS Comput Biol 18 e1010343 (2022)
  303. C4b Binding Protein Acts as an Innate Immune Effector Against Influenza A Virus. Varghese PM, Murugaiah V, Beirag N, Temperton N, Khan HA, Alrokayan SH, Al-Ahdal MN, Nal B, Al-Mohanna FA, Sim RB, Kishore U. Front Immunol 11 585361 (2020)
  304. Characterization of evolutionary changes in hemagglutinin of influenza H1N1 virus: a computational analysis. Rehman Z, Zafar R, Amir U, Niazi UH, Fahim A. Virusdisease 27 34-40 (2016)
  305. Crystal structure of the Propionibacterium acnes surface sialidase, a drug target for P. acnes-associated diseases. Yu ACY, Volkers G, Jongkees SAK, Worrall LJ, Withers SG, Strynadka NCJ. Glycobiology 32 162-170 (2022)
  306. Deep mutational scanning of influenza A virus neuraminidase facilitates the identification of drug resistance mutations in vivo. Wang S, Zhang T-h, Hu M, Tang K, Sheng L, Hong M, Chen D, Chen L, Shi Y, Feng J, Qian J, Sun L, Ding K, Sun R, Du Y. mSystems 8 e0067023 (2023)
  307. Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors. Ye J, Lin L, Xu J, Chan PK, Yang X, Ma C. Pharmaceuticals (Basel) 14 371 (2021)
  308. Development of Digital Droplet PCR Targeting the Influenza H3N2 Oseltamivir-Resistant E119V Mutation and Its Performance through the Use of Reverse Genetics Mutants. Van Poelvoorde LAE, Dufrasne FE, Van Gucht S, Saelens X, Roosens NHC. Curr Issues Mol Biol 45 2521-2532 (2023)
  309. Discovery of Novel Boron-Containing N-Substituted Oseltamivir Derivatives as Anti-Influenza A Virus Agents for Overcoming N1-H274Y Oseltamivir-Resistant. Jia R, Zhang J, Zhang J, Bertagnin C, Bonomini A, Guizzo L, Gao Z, Ji X, Li Z, Liu C, Ju H, Ma X, Loregian A, Huang B, Zhan P, Liu X. Molecules 27 6426 (2022)
  310. Dynamic residue interaction network analysis of the oseltamivir binding site of N1 neuraminidase and its H274Y mutation site conferring drug resistance in influenza A virus. Yadav M, Igarashi M, Yamamoto N. PeerJ 9 e11552 (2021)
  311. Evolution and Introductions of Influenza A Virus H1N1 in a Farrow-to-Finish Farm in Guatemala. Ortiz L, Geiger G, Ferreri L, Moran D, Alvarez D, Gonzalez-Reiche AS, Mendez D, Rajao D, Cordon-Rosales C, Perez DR. Microbiol Spectr 11 e0287822 (2023)
  312. Evolutionarily conserved residues at an oligomerization interface of the influenza A virus neuraminidase are essential for viral survival. Mok CK, Chen GW, Shih KC, Gong YN, Lin SJ, Horng JT, Hsu JT, Chen CJ, Shih SR. Virology 447 32-44 (2013)
  313. FPocketWeb: protein pocket hunting in a web browser. Kochnev Y, Durrant JD. J Cheminform 14 58 (2022)
  314. Impact of tetramerization on the ligand recognition of N1 influenza neuraminidase via MMGBSA approach. Bello M. Biopolymers 110 e23251 (2019)
  315. Implications of protein conformations to modifying novel inhibitor Oseltamivir for 2009 H1N1 influenza A virus by simulation and docking studies. Singh S, Malhotra AG, Jha M, Pandey KM. Virusdisease 29 461-467 (2018)
  316. In vivo mallard experiments indicate that zanamivir has less potential for environmental influenza A virus resistance development than oseltamivir. Nykvist M, Gillman A, Söderström Lindström H, Tang C, Fedorova G, Lundkvist Å, Latorre-Margalef N, Wille M, Järhult JD. J. Gen. Virol. (2017)
  317. Influenza A Virus Neuraminidase Inhibitors. Sriwilaijaroen N, Vavricka CJ, Kiyota H, Suzuki Y. Methods Mol Biol 2556 321-353 (2022)
  318. Inhibition effect of flavonoid compounds against neuraminidase expressed in Pichia pastoris. Nguyen TTH, Kang HK, Kim YM, Jang TS, Kim D. Biotechnol Bioprocess Eng 19 70-75 (2014)
  319. Inhibition of Influenza Virus Replication by Oseltamivir Derivatives. Chan RWY, Tao KP, Ye J, Lui KKY, Yang X, Ma C, Chan PKS. Pathogens 11 237 (2022)
  320. Kinetic, Thermodynamic, and Structural Analysis of Drug Resistance Mutations in Neuraminidase from the 2009 Pandemic Influenza Virus. Pokorná J, Pachl P, Karlukova E, Hejdánek J, Řezáčová P, Machara A, Hudlický J, Konvalinka J, Kožíšek M. Viruses 10 (2018)
  321. Locking the 150-cavity open: in silico design and verification of influenza neuraminidase inhibitors. Han N, Mu Y. PLoS ONE 8 e73344 (2013)
  322. Molecular docking, synthesis, and biological evaluation of naphthoquinone as potential novel scaffold for H5N1 neuraminidase inhibition. Sharma G, Vasanth Kumar S, Wahab HA. J. Biomol. Struct. Dyn. 36 233-242 (2018)
  323. Molecular modeling and phylogenetic analyses highlight the role of amino acid 347 of the N1 subtype neuraminidase in influenza virus host range and interspecies adaptation. Elli S, Raffaini G, Guerrini M, Kosakovsky Pond S, Matrosovich M. Front Microbiol 14 1309156 (2023)
  324. Molecular simulation study of the binding mechanism of [α-PTi2W10O40]7- for its promising broad-spectrum inhibitory activity to FluV-A neuraminidase. Wang J, Hu D, Su Z. Chin Sci Bull 55 2497-2504 (2010)
  325. Multiscale Simulations Examining Glycan Shield Effects on Drug Binding to Influenza Neuraminidase. Seitz C, Casalino L, Konecny R, Huber G, Amaro RE, McCammon JA. Biophys J 119 2275-2289 (2020)
  326. New insights into the neuraminidase-mediated hemagglutination activity of influenza A(H3N2) viruses. Gao R, Pascua PNQ, Nguyen HT, Chesnokov A, Champion C, Mishin VP, Wentworth DE, Gubareva LV. Antiviral Res 218 105719 (2023)
  327. Optimisation of Neuraminidase Expression for Use in Drug Discovery by Using HEK293-6E Cells. Campbell AC, Tanner JJ, Krause KL. Viruses 13 1893 (2021)
  328. Phylogenetic analysis of the neuraminidase gene reveals that the H5N1 strains prevalent in chickens during 2006 bird flu outbreaks in two regions of Maharashtra, India are genetically different. Danishuddin M, Khan AU. Genomics Proteomics Bioinformatics 7 57-61 (2009)
  329. Plasticity of the 340-Loop in Influenza Neuraminidase Offers New Insight for Antiviral Drug Development. Han N, Ng JTY, Li Y, Mu Y, Huang Z. Int J Mol Sci 21 (2020)
  330. Potentiometric Biosensors Based on Molecular-Imprinted Self-Assembled Monolayer Films for Rapid Detection of Influenza A Virus and SARS-CoV-2 Spike Protein. Lee WI, Subramanian A, Mueller S, Levon K, Nam CY, Rafailovich MH. ACS Appl Nano Mater 5 5045-5055 (2022)
  331. Quantitative Proteomics Analysis of Systemic Responses and Biological Mechanisms of ShuFengJieDu Capsule Using H1N1-Infected RAW264.7 Cells. Tao Z, Chen J, Su J, Wu S, Yuang Y, Yao H, Wong CCL, Lu H. ACS Omega 5 15417-15423 (2020)
  332. Residue-based design of small molecule inhibitor for H1N1, H5N1 and H7N1 mutants. Tou WI, Chang KL, Chang TT, Lee CC, Chen CY. J Mol Model 22 4 (2016)
  333. Secondary Metabolites from the Coral-Derived Fungus Aspergillus austwickii SCSIO41227 with Pancreatic Lipase and Neuraminidase Inhibitory Activities. Chen Y, He Y, Pang X, Zhou X, Liu Y, Yang B. Mar Drugs 21 567 (2023)
  334. Shikimic Acid Promotes Oligodendrocyte Precursor Cell Differentiation and Accelerates Remyelination in Mice. Lu F, Yin D, Pu Y, Liu W, Li Z, Shao Q, He C, Cao L. Neurosci Bull 35 434-446 (2019)
  335. Stepwise prediction and statistical screening: B-cell epitopes on neuraminidase of human avian H5N1 virus. Huang P, Yu S, Ke C. Chin Sci Bull 53 3642-3647 (2008)
  336. Structural and inhibitor sensitivity analysis of influenza B-like viral neuraminidases derived from Asiatic toad and spiny eel. Li L, Chai Y, Peng W, Li D, Sun L, Gao GF, Qi J, Xiao H, Liu WJ, von Itzstein M, Gao F. Proc Natl Acad Sci U S A 119 e2210724119 (2022)
  337. Structure-based design of 5'-substituted 1,2,3-triazolylated oseltamivir derivatives as potent influenza neuraminidase inhibitors. Wang P, Oladejo BO, Li C, Fu L, Zhang S, Qi J, Lv X, Li X. RSC Adv 11 9528-9541 (2021)
  338. Structure-based design of stabilized recombinant influenza neuraminidase tetramers. Ellis D, Lederhofer J, Acton OJ, Tsybovsky Y, Kephart S, Yap C, Gillespie RA, Creanga A, Olshefsky A, Stephens T, Pettie D, Murphy M, Sydeman C, Ahlrichs M, Chan S, Borst AJ, Park YJ, Lee KK, Graham BS, Veesler D, King NP, Kanekiyo M. Nat Commun 13 1825 (2022)
  339. Studies on the production of shikimic acid using the aroK knockout strain of Bacillus megaterium. Ghosh S, Mohan U, Banerjee UC. World J. Microbiol. Biotechnol. 32 127 (2016)
  340. Synthesis and Biological Evaluation of NH2-Sulfonyl Oseltamivir Analogues as Influenza Neuraminidase Inhibitors. Hu Y, Chen B, Lei Z, Zhao H, Zhu H, Quan P, Tian Y. Molecules 24 (2019)
  341. Synthesis of Trifluoromethyl-α,β-unsaturated Lactones and Pyrazolinones and Discovery of Influenza Virus Polymerase Inhibitors. Mizuta S, Makau JN, Kitagawa A, Kitamura K, Otaki H, Nishi K, Watanabe K. ChemMedChem 13 2390-2399 (2018)
  342. Targeting the Human Influenza a Virus: The Methods, Limitations, and Pitfalls of Virtual Screening for Drug-like Candidates Including Scaffold Hopping and Compound Profiling. Scior T, Cuanalo-Contreras K, Islas AA, Martinez-Laguna Y. Viruses 15 1056 (2023)
  343. The 2nd sialic acid-binding site of influenza A virus neuraminidase is an important determinant of the hemagglutinin-neuraminidase-receptor balance. Du W, Guo H, Nijman VS, Doedt J, van der Vries E, van der Lee J, Li Z, Boons GJ, van Kuppeveld FJM, de Vries E, Matrosovich M, de Haan CAM. PLoS Pathog. 15 e1007860 (2019)
  344. The hydrophobic side chain of oseltamivir influences type A subtype selectivity of neuraminidase inhibitors. Lin X, Qin-Hua C, Peng L, Chun-Lei L, Guang-De Y. Chem Biol Drug Des 91 105-115 (2018)
  345. Two new secolignans from the roots of Urtica fissa. Lu X, Li XQ, Qin HH, Feng BM, Cheng XH, Yang QX, Yu DY, Shi LY, Yu ZX, Fang XX. J Asian Nat Prod Res 21 165-170 (2019)
  346. Visible light powered self-disinfecting coatings for influenza viruses. Weng D, Qi H, Wu TT, Yan M, Sun R, Lu Y. Nanoscale 4 2870-2874 (2012)
  347. WaterKit: Thermodynamic Profiling of Protein Hydration Sites. Eberhardt J, Forli S. J Chem Theory Comput 19 2535-2556 (2023)
  348. Whole-Genome Sequence Approach and Phylogenomic Stratification Improve the Association Analysis of Mutations With Patient Data in Influenza Surveillance. Van Poelvoorde L, Vanneste K, De Keersmaecker SCJ, Thomas I, Van Goethem N, Van Gucht S, Saelens X, Roosens NHC. Front Microbiol 13 809887 (2022)
  349. Worth the Weight: Sub-Pocket EXplorer (SubPEx), a Weighted Ensemble Method to Enhance Binding-Pocket Conformational Sampling. Hellemann E, Durrant JD. J Chem Theory Comput 19 5677-5689 (2023)
  350. [The flexibility of the protein neuraminidase opens new possibilities for drug development]. von Grafenstein S, Liedl KR. Pharm Unserer Zeit 40 99-100 (2011)


Quick links